BHCM
SABS icon

Brevan Howard Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Brevan Howard Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,161
Closed -$227K – 2515
2026
Q1 		$227K Buy
+59,161
New +$236K ﹤0.01% 1819

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brevan Howard Capital Management's SABS Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 59,161 shares — an estimated $227K sold.

Brevan Howard Capital Management first reported a position in SABS in Q1 2026 and held it in 1 quarter. The position peaked at $227K in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 59,161 SAB Biotherapeutics shares in Q2 2026, an estimated $227K.
  • Brevan Howard Capital Management first reported a position in SAB Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's SAB Biotherapeutics position peaked at $227K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.